Proficio Capital Partners LLC bought a new stake in Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 11,895 shares of the technology company’s stock, valued at approximately $93,000.
Other large investors have also added to or reduced their stakes in the company. Victory Capital Management Inc. purchased a new position in shares of Cogent Biosciences during the 3rd quarter valued at approximately $113,000. Dynamic Technology Lab Private Ltd acquired a new stake in Cogent Biosciences in the third quarter valued at $134,000. Virtu Financial LLC bought a new position in Cogent Biosciences during the 3rd quarter valued at $147,000. New York State Common Retirement Fund raised its stake in shares of Cogent Biosciences by 10.5% in the 4th quarter. New York State Common Retirement Fund now owns 23,102 shares of the technology company’s stock valued at $180,000 after purchasing an additional 2,200 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Cogent Biosciences by 11.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 23,422 shares of the technology company’s stock worth $183,000 after purchasing an additional 2,371 shares during the last quarter.
Cogent Biosciences Stock Down 4.0 %
Shares of NASDAQ COGT opened at $7.29 on Friday. The stock has a market cap of $829.97 million, a P/E ratio of -2.94 and a beta of 1.80. The firm’s 50-day simple moving average is $8.07 and its 200 day simple moving average is $9.39. Cogent Biosciences, Inc. has a fifty-two week low of $5.73 and a fifty-two week high of $12.61.
Wall Street Analysts Forecast Growth
View Our Latest Research Report on COGT
About Cogent Biosciences
Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
See Also
- Five stocks we like better than Cogent Biosciences
- Following Congress Stock Trades
- 3 Undervalued Stocks You Can Buy at a Discount Now
- How to Short Nasdaq: An Easy-to-Follow Guide
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Receive News & Ratings for Cogent Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogent Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.